scispace - formally typeset
Journal ArticleDOI

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Ira M. Jacobson, +15 more
- 02 Aug 2014 - 
- Vol. 384, Iss: 9941, pp 403-413
TLDR
Treatment with simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in treatment-naive patients with HCV genotype 1 infection without worsening the adverse event profiles associated with peggylated interferon, as well as improving the intention-to-treat analysis.
About: 
This article is published in The Lancet.The article was published on 2014-08-02. It has received 447 citations till now. The article focuses on the topics: Simeprevir & Ribavirin.

read more

Citations
More filters
Journal ArticleDOI

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, +21 more
- 15 Nov 2014 - 
TL;DR: Combined simeprevir and sofosbuvir was efficacious and well tolerated in chronic HCV genotype 1 infections and sustained virological response 12 weeks after stopping treatment was achieved.
Journal ArticleDOI

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial

Stefan Zeuzem, +13 more
- 07 Jul 2015 - 
TL;DR: Grazoprevir and elbasvir were evaluated in a randomized, blinded, placebo-controlled trial in treatment-naive patients with hepatitis C virus (HCV) infection.
Journal ArticleDOI

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Michael Manns, +15 more
- 02 Aug 2014 - 
TL;DR: The primary efficacy endpoint was sustained virological response at 12 weeks after the planned end of treatment (SVR12) and the incidences of adverse events were similar in the simeprevir and placebo groups at 12 Weeks and for the entire treatment, irrespective of the peginterferon alfa used.
Journal ArticleDOI

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

Christoph Sarrazin
- 01 Feb 2016 - 
TL;DR: Geno- and phenotypic resistance testing as well as clinical data on the importance of RAVs for conventional triple therapies with sofosbuvir, simeprevir, and daclatasvir and available interferon-free DAA combinations are discussed.
Journal ArticleDOI

Lancet Seminar – Hepatitis C

Daniel P. Webster, +2 more
- 21 Mar 2015 - 
TL;DR: Advances in HCV cell culture have enabled improved understanding of HCV virology, which has led to development of many new direct-acting antiviral drugs that target key components of virus replication, allowing for simplified and shortened treatments for HCV that can be given as oral regimens with increased tolerability and efficacy.
References
More filters
Journal ArticleDOI

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

Lenore Sawyer Radloff
- 01 Jun 1977 - 
TL;DR: The CES-D scale as discussed by the authors is a short self-report scale designed to measure depressive symptomatology in the general population, which has been used in household interview surveys and in psychiatric settings.
Journal Article

EuroQol : a new facility for the measurement of health-related quality of life

A. Williams
- 01 Jan 1990 - 
Journal ArticleDOI

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Rafael Lozano, +195 more
- 15 Dec 2012 - 
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.

The Global Burden of Disease Study

Christopher J L Murray, +1 more
Journal ArticleDOI

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Michael W. Fried, +13 more
- 26 Sep 2002 - 
TL;DR: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferonAlfa- 2b plus Ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interfer on alfa -2b plus ribvirin or pegin terferonalfa-3a alone.
Related Papers (5)

Sofosbuvir for previously untreated chronic hepatitis C infection

Eric Lawitz, +23 more
- 15 May 2013 - 

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

Nezam H. Afdhal, +23 more
- 14 May 2014 - 

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, +24 more
- 16 Apr 2014 - 

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Sprint Investigators
- 30 Mar 2011 - 

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

Ira M. Jacobson, +23 more
- 22 Jun 2011 -